Showing results (71-80 of 389) with videos related to
Sort By:
Pageof 39
Cancer Science|July 26, 2011
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumorsShunji Takahashi, Masaki Miyazaki, Isamu Okamoto, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 27, 2010
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancerMasayuki Takeda, Isamu Okamoto, Yoshihiko Fujita, et al.Radiology|October 24, 2017
Prediction of Therapeutic Effect of Chemotherapy for NSCLC Using Dual-Input Perfusion CT Analysis: Comparison among Bevacizumab Treatment, Two-Agent Platinum-based Therapy without Bevacizumab, and Other Non-Bevacizumab Treatment GroupsHidetake Yabuuchi, Satoshi Kawanami, Eiji Iwama, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cellsTsutomu Iwasa, Isamu Okamoto, Minoru Suzuki, et al.Japanese Journal of Clinical Oncology|May 29, 2014
A phase I study of split-dose cisplatin and etoposide with concurrent accelerated hyperfractionated thoracic radiotherapy in elderly patients with limited-disease small cell lung cancerKunio Okamoto, Isamu Okamoto, Masayuki Takeda, et al.Cancer Science|September 27, 2018
Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assayShinichi Kimura, Kentaro Tanaka, Taishi Harada, et al.Journal of Thoracic Disease|July 21, 2025
Diagnostic yield and safety of transbronchial lung cryobiopsy using 1.7-mm probes in interstitial lung diseaseAi Koike, Kazuya Tsubouchi, Satoshi Nakamura, et al.Lung Cancer (Amsterdam, Netherlands)|January 2, 2018
Prevalence of Delta-like protein 3 expression in patients with small cell lung cancerKentaro Tanaka, Kumiko Isse, Tomomichi Fujihira, et al.Molecular Cancer Therapeutics|April 29, 2010
Synergistic antitumor effect of S-1 and HER2-targeting agents in gastric cancer with HER2 amplificationJunko Tanizaki, Isamu Okamoto, Ken Takezawa, et al.Cancer Chemotherapy and Pharmacology|July 9, 2020
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancerToshio Shimizu, Kazuto Nishio, Kazuko Sakai, et al.Pageof 39